- PERSEUS – EFC 16035
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) – To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)
If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com
https://www.clinicaltrials.gov/ct2/show/NCT04458051?titles=PERSEUS
- ASPIRE
The study is being conducted to determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). A secondary Aim is to determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale. ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF (CHA2DS2-VASc score ≥ 2). Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.
If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com
https://www.clinicaltrials.gov/ct2/show/NCT03907046
- R3918-MG
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com
- Librexia
A Phase 3, Randomized, Double-Blind, Parallel-Group, Pacebo-controlled study to determine the efficacy and safety of Milvexian, an Oral Factor Xia Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- Roche
Phase III, randomized, placebo controlled study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as add-on therapy to standard of care for the treatment of gMG.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- Alexion
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ALXN1720 in adults with generalized Myasthenia Gravis.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- UCB
Phase IIIB, multicenter, open-label, single-arm study to evaluate the safety, tolerability, and efficacy of Zilucoplan in participants with generalized Myasthenia Gravis switching from intravenous complement component 5 inhibitors to subcutaneous Zilucoplan.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com